Privia Health Group (NASDAQ:PRVA) Director Sells $1,463,387.28 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 53,722 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $27.24, for a total transaction of $1,463,387.28. Following the sale, the director owned 68,188 shares in the company, valued at $1,857,441.12. This represents a 44.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Thursday, July 2nd, Matthew Shawn Morris sold 59,037 shares of Privia Health Group stock. The stock was sold at an average price of $27.33, for a total value of $1,613,481.21.
• On Monday, June 29th, Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total value of $1,601,159.96.
• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total value of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total value of $25,384.32.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $27.77 on Friday. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of 173.57, a PEG ratio of 2.15 and a beta of 0.83. The business has a 50 day simple moving average of $23.71 and a 200-day simple moving average of $23.11. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $27.81.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRVA. GAMMA Investing LLC boosted its position in Privia Health Group by 14.0% in the 2nd quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock valued at $124,000 after buying an additional 592 shares during the period. State of Alaska Department of Revenue increased its position in shares of Privia Health Group by 1.3% during the fourth quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock worth $1,558,000 after acquiring an additional 823 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Privia Health Group by 8.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after acquiring an additional 840 shares during the period. ProShare Advisors LLC raised its stake in shares of Privia Health Group by 4.1% during the fourth quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock valued at $535,000 after acquiring an additional 898 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Privia Health Group by 5.9% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after purchasing an additional 903 shares during the period. Institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Zacks Research lowered shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Barclays reduced their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Evercore set a $26.00 target price on shares of Privia Health Group in a report on Wednesday, April 8th. Canaccord Genuity Group dropped their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.15.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.